CTChung-Jung Tsai

Chung-Jung Tsai

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Chung-Jung Tsai has a total of 22 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Neurodevelopmental disorders and cancer networks share pathways; but differ in mechanisms, signaling strength, and outcome

    by Bengi Ruken Yavuz, M Kaan Arici, Habibe Cansu Demirel, Chung-Jung Tsai, Hyunbum Jang, Ruth Nussinov, Nurcan Tuncbag

    Neurodevelopmental disorders (NDDs) and cancer are connected, with immunity as their common factor. Their clinical presentations differ; however, individuals with NDDs are more likely to acquire cancer. Schizophrenia patients have ∼50% increased risk; autistic individuals also face an increased cancer likelihood. NDDs are associated with specific brain cell types at specific locations, emerging at certain developmental time windows during brain evolution. Their related mutations are germline; cancer mutations are sporadic, emerging during life. At the same time, NDDs and cancer share proteins, pathways, and mutations. Here we ask exactly which features they share, and how despite their commonality, they differ in outcomes. Our pioneering bioinformatics exploration of the mutations, reconstructed disease-specific networks, pathways, and transcriptome profiles of autism spectrum disorder (ASD) and cancers, points to elevated signal strength in pathways related to proliferation in cancer, and differentiation in ASD. Signaling strength, not the activating mutation, is the key factor in deciding cancer versus NDDs.

  • Open Access

    Pan-cancer clinical impact of latent drivers from double mutations

    by Bengi Ruken Yavuz, Chung-Jung Tsai, Ruth Nussinov, Nurcan Tuncbag

    Here, we discover potential ‘latent driver’ mutations in cancer genomes. Latent drivers have low frequencies and minor observable translational potential. As such, to date they have escaped identification. Their discovery is important, since when paired in cis, latent driver mutations can drive cancer. Our comprehensive statistical analysis of the pan-cancer mutation profiles of ~60,000 tumor sequences from the TCGA and AACR-GENIE cohorts identifies significantly co-occurring potential latent drivers. We observe 155 same gene double mutations of which 140 individual components are cataloged as latent drivers. Evaluation of cell lines and patient-derived xenograft response data to drug treatment indicate that in certain genes double mutations may have a prominent role in increasing oncogenic activity, hence obtaining a better drug response, as in PIK3CA. Taken together, our comprehensive analyses indicate that same-gene double mutations are exceedingly rare phenomena but are a signature for some cancer types, e.g., breast, and lung cancers. The relative rarity of doublets can be explained by the likelihood of strong signals resulting in oncogene-induced senescence, and by doublets consisting of non-identical single residue components populating the background mutational load, thus not identified.


  • Open Access

    A New View of Activating Mutations in Cancer

    by Ruth Nussinov, Chung-Jung Tsai, Hyunbum Jang

    A vast effort has been invested in the identification of driver mutations of cancer. However, recent studies and observations call into question whether the activating mutations or the signal strength are the major determinant of tumor development. The data argue that signal strength determines cell fate, not the mutation that initiated it. In addition to activating mutations, factors that can impact signaling strength include (i) homeostatic mechanisms that can block or enhance the signal, (ii) the types and locations of additional mutations, and (iii) the expression levels of specific isoforms of genes and regulators of proteins in the pathway. Because signal levels are largely decided by chromatin structure, they vary across cell types, states, and time windows. A strong activating mutation can be restricted by low expression, whereas a weaker mutation can be strengthened by high expression. Strong signals can be associated with cell proliferation, but too strong a signal may result in oncogene-induced senescence. Beyond cancer, moderate signal strength in embryonic neural cells may be associated with neurodevelopmental disorders, and moderate signals in aging may be associated with neurodegenerative diseases, like Alzheimer's disease. The challenge for improving patient outcomes therefore lies in determining signaling thresholds and predicting signal strength.


  • Open Access

    Abstract 2919: The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia

    by Yonglan Liu, Hyunbum Jang, Mingzhen Zhang, Chung-Jung Tsai, Ryan Maloney, Ruth Nussinov

    Philadelphia chromosomes 9 and 22 encode BCR and ABL1 genes, respectively. Translocation mutation of two chromosomes generates the fused BCR-ABL1 gene. The resulting fused gene encodes the chimeric BCR-ABL oncoprotein with constitutively enhanced and dysregulated tyrosine activity to disturb different cell signaling. Ras/MAPK is a significant pathway in mediating cell proliferation and its hyperactivation is responsible for malignant transformation in cancer. Autophosphorylation Y177 (pY177) of BCR protein stimulates the direct binding of an adaptor protein GRB2, which is involved in Ras/MAPK pathway. In BCR-ABL-associated Ras/MAPK signaling pathway, BCR-ABL can target GRB2 through the interaction of its pY motif with GRB2 SH2 domain, followed by SOS recruitment to the plasma membrane by GRB2. The resulting BCR-ABL/GRB2/SOS assembly stimulates the transformation of inactive GDP-bound form of Ras to the active GTP-bound state, which causes the constitutive activation of the downstream components of Raf/MEK/ERK. Despite a number of biophysical experiments have showed that BCR-ABL is able to recruit GRB2, the molecular-level understanding of how the two proteins interact with each other remains to be elucidated. In this work, we used molecular modeling and molecular dynamics (MD) simulations to study the structural basis for the binding between BCR-ABL and GRB2 SH2 domain to explain CML oncogenesis at the atomic level. Different pY/Y-peptide-SH2 complex models have been constructed and their binding specificity and affinity were compared. Simulation results showed that phosphorylated BCR (pBCR) specifically binds to GRB2 SH2 domain through its five-residue 176FpYVNV180 motif. GRB2 SH2 domain contains two binding pockets: the pY-binding pocket for the phosphate recognition and the specificity pocket for the selection of Asn. pY177 triggers the binding through the interaction in pY-binding pocket. The interaction in specificity pocket determines the binding specificity, which is regulated by N179 in pBCR and W121 in EF loop of GRB2 SH2 domain. In addition, the interaction in the specificity pocket experiences conformation selection for both the bound motif in pBCR and GRB2 SH2 domain; the binding motif adopts type I β-turn conformation and the specificity pocket of GRB2 SH2 domain displays the closed conformation. This specific binding mode between pBCR and GRB2 SH2 domain is similar with that between phosphorylated EGFR (pEGFR) and GRB2 SH2 domain. Residues adjacent to the pY and Arg residue at the +2 position C-terminal to pY in the binding motifs influence the binding affinity of a pY-peptide to GRB2 SH2 domain, explaining why pBCR shows stronger affinity to GRB2 SH2 domain than pEGFR. Our study supports the BCR-ABL oncoprotein recruitment of GRB2 for the induction of CML through Ras/MAPK pathway and provides deeply understanding of the specific interaction of the pY motif with GRB2 SH2 domain at atomic level. Citation Format: Yonglan Liu, Hyunbum Jang, Mingzhen Zhang, Chung-Jung Tsai, Ryan Maloney, Ruth Nussinov. The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2022; 2022 Apr 8-13. Philadelphia (PA): AACR; Cancer Res 2022;82(12_Suppl):Abstract nr 2919.

  • Open Access

    The structural basis of BCR-ABL recruitment of GRB2 in chronic myelogenous leukemia

    by Yonglan Liu, Hyunbum Jang, Mingzhen Zhang, Chung-Jung Tsai, Ryan Maloney, Ruth Nussinov


  • Open Access

    Phosphorylation and Driver Mutations in PI3Kα and PTEN Autoinhibition

    by Ruth Nussinov, Mingzhen Zhang, Chung-Jung Tsai, Hyunbum Jang

    PI3K and PTEN are the second and third most highly mutated proteins in cancer following only p53. Their actions oppose each other. PI3K phosphorylates signaling lipid PIP2 to PIP3. PTEN dephosphorylates it back. Driver mutations in both proteins accrue PIP3. PIP3 recruits AKT and PDK1 to the membrane, promoting cell-cycle progression. Here we review phosphorylation events and mutations in autoinhibition in PI3K and PTEN from the structural standpoint. Our purpose is to clarify how they control the autoinhibited states. In autoinhibition, a segment or a subunit of the protein occludes its functional site. Protein–protein interfaces are often only marginally stable, making them sensitive to changes in conditions in living cells. Phosphorylation can stabilize or destabilize the interfaces. Driver mutations commonly destabilize them. In analogy to “passenger mutations,” we coin “passenger phosphorylation” to emphasize that the presence of a phosphorylation recognition sequence logo does not necessarily imply function. Rather, it may simply reflect a statistical occurrence. In both PI3K and PTEN, autoinhibiting phosphorylation events are observed in the occluding “piece.” In PI3Kα, the “piece” is the p85α subunit. In PTEN, it is the C-terminal segment. In both enzymes the stabilized interface covers the domain that attaches to the membrane. Driver mutations that trigger rotation of the occluding piece or its deletion prompt activation. To date, both enzymes lack specific, potent drugs. We discuss the implications of detailed structural and mechanistic insight into oncogenic activation and how it can advance allosteric precision oncology.


  • Open Access

    Protein ensembles link genotype to phenotype

    by Ruth Nussinov, Chung-Jung Tsai, Hyunbum Jang

    Classically, phenotype is what is observed, and genotype is the genetic makeup. Statistical studies aim to project phenotypic likelihoods of genotypic patterns. The traditional genotype-to-phenotype theory embraces the view that the encoded protein shape together with gene expression level largely determines the resulting phenotypic trait. Here, we point out that the molecular biology revolution at the turn of the century explained that the gene encodes not one but ensembles of conformations, which in turn spell all possible gene-associated phenotypes. The significance of a dynamic ensemble view is in understanding the linkage between genetic change and the gained observable physical or biochemical characteristics. Thus, despite the transformative shift in our understanding of the basis of protein structure and function, the literature still commonly relates to the classical genotype–phenotype paradigm. This is important because an ensemble view clarifies how even seemingly small genetic alterations can lead to pleiotropic traits in adaptive evolution and in disease, why cellular pathways can be modified in monogenic and polygenic traits, and how the environment may tweak protein function.


  • Open Access

    Structural host-microbiota interaction networks

    by Emine Guven-Maiorov, Chung-Jung Tsai, Ruth Nussinov

    Hundreds of different species colonize multicellular organisms making them “metaorganisms”. A growing body of data supports the role of microbiota in health and in disease. Grasping the principles of host-microbiota interactions (HMIs) at the molecular level is important since it may provide insights into the mechanisms of infections. The crosstalk between the host and the microbiota may help resolve puzzling questions such as how a microorganism can contribute to both health and disease. Integrated superorganism networks that consider host and microbiota as a whole–may uncover their code, clarifying perhaps the most fundamental question: how they modulate immune surveillance. Within this framework, structural HMI networks can uniquely identify potential microbial effectors that target distinct host nodes or interfere with endogenous host interactions, as well as how mutations on either host or microbial proteins affect the interaction. Furthermore, structural HMIs can help identify master host cell regulator nodes and modules whose tweaking by the microbes promote aberrant activity. Collectively, these data can delineate pathogenic mechanisms and thereby help maximize beneficial therapeutics. To date, challenges in experimental techniques limit large-scale characterization of HMIs. Here we highlight an area in its infancy which we believe will increasingly engage the computational community: predicting interactions across kingdoms, and mapping these on the host cellular networks to figure out how commensal and pathogenic microbiota modulate the host signaling and broadly cross-species consequences.


  • THE LEVELS OF POLYBROMINATED DIPHENYL ETHERS IN FOODSTUFFS AND HUMAN EXPOSURE

    by I-Fang Mao, Kai-Chi Yang, Chin-Chi Mao, Chung-Jung Tsai, Mei-Lien Chen

    Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences. Environmental Health Perspectives is an Open Access journal published by the National Institute of Environmental Health Sciences.